-
Electronic (PDF)
-
Site License
-
Enterprisewide
Testicular Cancer - Pipeline Review, H1 2012
Global Markets Direct, April 2012, Pages: 54
Testicular Cancer – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Testicular Cancer - Pipeline Review, H1 2012', provides an overview of the Testicular Cancer therapeutic pipeline. This report provides information on the therapeutic development for Testicular Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Testicular Cancer . 'Testicular Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Testicular Cancer .
- A review of the Testicular Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Testicular Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Testicular Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Testicular Cancer pipeline depth and focus of Testicular Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Testicular Cancer Therapeutic Products under Development, Key Players in Testicular Cancer Therapeutics, Testicular Cancer Pipeline Overview, Testicular Cancer Pipeline, Testicular Cancer Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Testicular Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Testicular Cancer
Testicular Cancer Therapeutics under Development by Companies
Testicular Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Testicular Cancer Therapeutics – Products under Development by Companies
Testicular Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Testicular Cancer Therapeutics Development
NsGene A/S
ZIOPHARM Oncology, Inc.
Testicular Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NsG6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide + Bleomycin + Taxol + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatinum + Vinblastine + Bleomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBOP + BEP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Ifosfamide + Vinblastine + Autologous Bone marrow Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide + Ifosfamide + Paclitaxel + Autologous Bone Marrow Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dasatinib + Ifosfamide + Carboplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Paclitaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amsacrine + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Cyclophosphamide + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zymafos + Etoposide + Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testicular Cancer Therapeutics – Drug Profile Updates
Testicular Cancer Therapeutics – Discontinued Products
Testicular Cancer Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Testicular Cancer, H1 2012
Products under Development for Testicular Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
NsGene A/S, H1 2012
ZIOPHARM Oncology, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Testicular Cancer Therapeutics – Drug Profile Updates
Testicular Cancer Therapeutics – Discontinued Products
Testicular Cancer Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Testicular Cancer, H1 2012
Products under Development for Testicular Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
